BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34132463)

  • 1. Next-generation sequencing in two cases of de novo acute basophilic leukaemia.
    Shimizu T; Kondo T; Nannya Y; Watanabe M; Kitawaki T; Shindo T; Hishizawa M; Yamashita K; Ogawa S; Takaori-Kondo A
    J Cell Mol Med; 2021 Jul; 25(14):7095-7099. PubMed ID: 34132463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen Expression Varies Significantly between Molecular Subgroups of Acute Myeloid Leukemia Patients: Clinical Applicability Is Hampered by Establishment of Relevant Cutoffs.
    Herborg LL; Nederby L; Brøndum RF; Hansen M; Hokland P; Roug AS
    Acta Haematol; 2021; 144(3):275-284. PubMed ID: 33271547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation into acute basophilic leukaemia in a patient with myelodysplastic syndrome.
    Yamagata T; Miwa A; Eguchi M; Kitagawa S; Muroi K; Hatake K; Suda T; Sakamoto S; Miura Y
    Br J Haematol; 1995 Mar; 89(3):650-2. PubMed ID: 7734371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute basophilic leukemia: case report.
    Gupta R; Jain P; Anand M
    Am J Hematol; 2004 Jun; 76(2):134-8. PubMed ID: 15164378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD117/CD34 expression in leukemic blasts.
    Wells SJ; Bray RA; Stempora LL; Farhi DC
    Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.
    Ducassou S; Prouzet-Mauléon V; Deau MC; Brunet de la Grange P; Cardinaud B; Soueidan H; Quelen C; Brousset P; Pasquet JM; Moreau-Gaudry F; Arock M; Mahon FX; Lippert E
    J Pathol; 2017 Jul; 242(3):347-357. PubMed ID: 28418072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased CD177
    Alayed K; Meyerson HJ
    Leuk Res; 2022 Jan; 112():106752. PubMed ID: 34896936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease.
    Scolnik MP; Morilla R; de Bracco MM; Catovsky D; Matutes E
    Leuk Res; 2002 Jul; 26(7):615-9. PubMed ID: 12008077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.
    Manchev VT; Bouzid H; Antony-Debré I; Leite B; Meurice G; Droin N; Prebet T; Costello RT; Vainchenker W; Plo I; Diop M; Macintyre E; Asnafi V; Favier R; Baccini V; Raslova H
    J Cell Mol Med; 2017 Jun; 21(6):1237-1242. PubMed ID: 27997762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and
    Dannheim KC; Pozdnyakova O; Dal Cin P; Weinberg OK
    J Clin Pathol; 2018 Dec; 71(12):1051-1059. PubMed ID: 30171088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.
    Ehninger A; Kramer M; Röllig C; Thiede C; Bornhäuser M; von Bonin M; Wermke M; Feldmann A; Bachmann M; Ehninger G; Oelschlägel U
    Blood Cancer J; 2014 Jun; 4(6):e218. PubMed ID: 24927407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Basophilic Leukemia: Recent Molecular and Diagnostic Update.
    Singh G
    Cureus; 2022 Jun; 14(6):e26054. PubMed ID: 35865433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute basophilic leukaemia: eight unsuspected new cases diagnosed by electron microscopy.
    Shvidel L; Shaft D; Stark B; Shtalrid M; Berrebi A; Resnitzky P
    Br J Haematol; 2003 Mar; 120(5):774-81. PubMed ID: 12614208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.